+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hematopoietic Stem Cell Transplantation - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 62 Pages
  • September 2022
  • Region: Global
  • DelveInsight
  • ID: 5525122
This ‘Hematopoietic Stem Cell Transplantation (HSCT) Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the HSCT historical and forecasted epidemiology as well as the HSCT epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hematopoietic Stem Cell Transplantation (HSCT) Understanding

Hematopoietic Stem Cell Transplantation (HSCT) Overview

Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases. HSCs are immature blood cells found in the peripheral blood and the bone marrow. These are also called blood stem cells. These are produced in the bone marrow and can develop into any type of blood cell required by the body. Stem cells divide and mature, replacing older and worn-out blood cells.

Hematopoietic Stem Cell Transplantation (HSCT) Procedure

The procedure of HSCT includes donor matching, mobilization, harvesting, conditioning, and infusion. The selection of a donor is an essential factor in the success of hematopoietic cell transplantation. There are many possible choices for an allogeneic HSC donor, which are as follows:
  • Matched donor - A donor with a comparable genetic makeup to the patient is preferable to assist or limit the issues that the expected immunological reaction might create. Siblings are usually the only members of the family. They may be matched entirely at the critical genes known as the human leukocyte antigen or HLA genes, which are proteins located on cellular surfaces.
  • Matched unrelated donor - If no siblings are available, testing their blood does not indicate a match or sibling donors are deemed unsuitable, a matched unrelated donor may be utilized. The search for a suitable donor can be carried out utilizing transplant registries worldwide.

Hematopoietic Stem Cell Transplantation (HSCT) Indications

Indications for HSCT have been bifurcated into malignant and nonmalignant diseases.
  • Malignant disease
  • Multiple Myeloma - Studies have shown increased overall survival and progression-free survival in patients younger than 65 when consolidation therapy with melphalan is initiated, followed by ASCT and lenalidomide maintenance therapy. The study showed a favorable outcome of high-dose melphalan plus stem-cell transplantation compared with consolidation therapy with melphalan, prednisone, and lenalidomide (MPR). It also showed a better outcome in patients who received maintenance therapy with lenalidomide.
  • Hodgkin and Non-Hodgkin Lymphoma - Studies have shown that chemotherapy followed by ASCT in cases of recurrent lymphomas (HL and NHL) that do not respond to conventional chemotherapy has better outcomes. A randomized controlled trial by Schmitz et al. showed a better 3-year outcome of high-dose chemotherapy with ASCT compared to aggressive conventional chemotherapy in relapsed chemo sensitive Hodgkin lymphoma. However, the overall survival was not significantly different between the two groups. The number of hematopoietic SCT recipients comes second after multiple myeloma, according to CIBMTR.

Hematopoietic Stem Cell Transplantation (HSCT) Epidemiology Perspective

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Hematopoietic Stem Cell Transplantation, Type-specific Cases of Hematopoietic Stem Cell Transplantation, and Total Cases of Hematopoietic Stem Cell Transplantation by Indication scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Hematopoietic Stem Cell Transplantation (HSCT) Detailed Epidemiology Segmentation

  • In 2021, the total cases of HSCT in the 7MM countries were 55,999, and these cases are anticipated to increase during the study period. The US accounted for 23,971 cases of HSCT in 2021.
  • Among the European countries, Germany had the highest number of cases of HSCT in 2021, i.e., 7,085 cases, followed by Italy which had 5,625 cases in 2021. On the other hand, Spain had the lowest number of cases of HSCT, i.e. 3,439 cases in 2021.
  • In terms of type-specific cases of HSCT, the percentage of autologous HSCT cases is more in comparison to allogeneic HSCT across the 7MM except for Japan.
  • Japan, in 2021, accounted for 5,872 cases of HSCT, which is expected to increase during the study period.
  • In terms of indications for HSCT, multiple myeloma/plasma cell disorders bags the largest pool among all the considered indications in the 7MM except for Japan

Scope of the Report

  • The report covers a descriptive overview of HSCT, explaining its procedure, types, indications, and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the HSCT risk and burden.
  • The report provides the segmentation of the epidemiology for 7MM by segmented by ‘Total Cases of Hematopoietic Stem Cell Transplantation, Type-specific Cases of Hematopoietic Stem Cell Transplantation, and Total Cases of Hematopoietic Stem Cell Transplantation by Indication'.

Report Highlights

  • 11-Year Forecast of Hematopoietic Stem Cell Transplantation
  • 7MM Coverage
  • Total Cases of Hematopoietic Stem Cell Transplantation
  • Type-specific Cases of Hematopoietic Stem Cell Transplantation
  • Total Cases of Hematopoietic Stem Cell Transplantation by Indication

Key Questions Answered

  • What are the risk, burdens, and unmet needs of HSCT?
  • What is the historical HSCT patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of HSCT at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HSCT?
  • Out of the countries mentioned above, which country would have the highest cases of HSCT during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The HSCT report will allow the user to -
  • Develop business strategies by understanding the trends, shaping and driving the 7MM HSCT epidemiology.
  • The HSCT epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The HSCT epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered

  • The United States
  • EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Table of Contents

1. Key Insights2. Report Introduction
3. Hematopoietic Stem Cell Transplantation (HSCT) Overview at a Glance
3.1. Patient Share (%) Distribution of Hematopoietic Stem Cell Transplantation (HSCT) by Regimen/Therapies in the 7MM in 2019
3.2. Patient Share (%) Distribution of Hematopoietic Stem Cell Transplantation (HSCT) by Regimen/Therapies in the 7MM in 2032
4. Hematopoietic Stem Cell Transplantation (HSCT): Future Prospects5. Executive Summary of Hematopoietic Stem Cell Transplantation (HSCT)6. Key events
7. Disease Background and Overview
7.1. Introduction
7.2. Types of HSCT
7.3. Procedure of HSCT
7.3.1. Donor matching
7.3.2. Mobilization
7.3.3. Harvesting
7.3.4. Conditioning
7.3.5. Infusion
7.4. Indications for HSCT
7.5. Complications and side-effects associated with HSCT
8. Treatment and Management
8.1. Treatment Algorithm
8.2. Treatment Guidelines for HSCT
8.2.1. NCCN Guidelines for the HSCT
9. Methodology
10. Epidemiology and Patient Population
10.1. Key Findings
10.2. Assumptions and Rationale
10.3. Epidemiology Scenario: 7MM
10.3.1. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the 7MM
10.4. The United States
10.4.1. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States
10.4.2. Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States
10.4.3. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the United States
10.5. EU-5 Epidemiology
10.5.1. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5
10.5.2. Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5
10.5.3. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the EU-5
10.6. Japan Epidemiology
10.6.1. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan
10.6.2. Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan
10.6.3. Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in Japan
11. Appendix
11.1. Report Methodology
11.2. Bibliography
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of Hematopoietic Stem Cell Transplantation (HSCT), Epidemiology, and Key Events (2019-2032)
Table 2: Key Events
Table 3: Pre-transplant Recipient Evaluation
Table 4: Hematopoietic Cell Mobilization Regimen
Table 5: Myeloablative Regimens
Table 6: Non-myeloablative Regimens
Table 7: Reduced-intensity Conditioning Regimens
Table 8: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the 7MM (2019-2032)
Table 9: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States (2019-2032)
Table 10: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States (2019-2032)
Table 11: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the United States (2019-2032)
Table 12: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5 (2019-2032)
Table 13: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5 (2019-2032)
Table 14: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the EU-5
Table 15: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan (2019-2032)
Table 16: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan (2019-2032)
Table 17: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in Japan (2019-2032)
List of Figures
Figure 1: Different Types of Stem Cells in the Body
Figure 2: Treatment Algorithm for Patients Eligible for AHSCT
Figure 3: Treatment Algorithm for Patients Not Eligible for AHSCT
Figure 4: HSC Mobilization
Figure 5: Conditioning and Post-transplant Follow-up for HSCT
Figure 6: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the 7MM (2019-2032)
Figure 7: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States (2019-2032)
Figure 8: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the United States (2019-2032)
Figure 9: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the United States (2019-2032)
Figure 10: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5 (2019-2032)
Figure 11: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in the EU-5 (2019-2032)
Figure 12: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in the EU-5 (2019-2032)
Figure 13: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan (2019-2032)
Figure 14: Type-specific Cases of Hematopoietic Stem Cell Transplantation (HSCT) in Japan (2019-2032)
Figure 15: Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications in Japan (2019-2032)